Targeting heat shock proteins in cancer: A promising therapeutic approach

International Journal of Molecular Sciences

Volumn 18, Issue 9, 2017, Pages

  Chatterjee, Suman ^a   Burns, Timothy F ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; Heat shock proteins (HSPs); HSP70; HSP90; HSP90 inhibitors; Oncogenes

Indexed keywords

2 AMINO 6 CHLORO 9 [(4 METHOXY 3,5 DIMETHYL 2 PYRIDINYL)METHYL]PURINE; 4 [[2 CARBAMOYL 5 (4,5,6,7 TETRAHYDRO 6,6 DIMETHYL 4 OXO 3 (TRIFLUOROMETHYL) 1H INDAZOL 1 YL)PHENYL]AMINO]CYCLOHEXYL GLYCINATE; ALVESPIMYCIN; ANTINEOPLASTIC AGENT; CHAPERONE; CHAPERONIN 60; DEBIO 0932; DS 2248; GANETESPIB; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK TRANSCRIPTION FACTOR 1; KW 2478; LUMINESPIB; MPC 3100; ONALESPIB; PU H71; RETASPIMYCIN; TANESPIMYCIN; TAS 116; UNCLASSIFIED DRUG; XL 888;

CANCER THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); DEREGULATION; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; NEOPLASM; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN PROCESSING; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; DRUG DEVELOPMENT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIGENE FAMILY; PATHOLOGY; PHYSIOLOGICAL STRESS; PRECLINICAL STUDY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; MOLECULAR TARGETED THERAPY; MULTIGENE FAMILY; NEOPLASMS; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 85029713475     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18091978     Document Type: Review

References (304)

1. Jaattela, M. Heat shock proteins as cellular lifeguards. Ann. Med. 1999, 31, 261-271
2. Jego, G.; Hazoume, A.; Seigneuric, R.; Garrido, C. Targeting heat shock proteins in cancer. Cancer Lett. 2013, 332, 275-285
3. Beere, H.M. The stress of dying: The role of heat shock proteins in the regulation of apoptosis. J. Cell Sci. 2004, 117, 2641-2651
4. Lindquist, S.; Craig, E.A. The heat-shock proteins. Annu. Rev. Genet. 1988, 22, 631-677
5. Nylandsted, J.; Brand, K.; Jaattela, M. Heat shock protein 70 is required for the survival of cancer cells. Ann. N. Y. Acad. Sci. 2000, 926, 122-125
6. Liu, T.; Daniels, C.K.; Cao, S. Comprehensive review on the HSC70 functions interactions with related molecules and involvement in clinical diseases and therapeutic potential. Pharmacol. Ther. 2012, 136, 354-374
7. Macario, A.J.; Conway de Macario, E. Molecular chaperones: Multiple functions pathologies and potential applications. Front. Biosci. A J. Virtual Libr. 2007, 12, 2588-2600
8. Chatterjee, S.; Bhattacharya, S.; Socinski, M.A.; Burns, T.F. HSP90 inhibitors in lung cancer: Promise still unfulfilled. Clin. Adv. Hematol. Oncol. 2016, 14, 346-356
9. Jolly, C.; Morimoto, R.I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl. Cancer Inst. 2000, 92, 1564-1572
10. Lianos, G.D.; Alexiou, G.A.; Mangano, A.; Mangano, A.; Rausei, S.; Boni, L.; Dionigi, G.; Roukos, D.H. The role of heat shock proteins in cancer. Cancer Lett. 2015, 360, 114-118
11. Wang, X.; Chen, M.; Zhou, J.; Zhang, X. HSP27, 70 and 90 anti-apoptotic proteins in clinical cancer therapy. Int. J. Oncol. 2014, 45, 18-30
12. Wu, J.; Liu, T.; Rios, Z.; Mei, Q.; Lin, X.; Cao, S. Heat Shock Proteins and Cancer. Trends Pharmacol. Sci. 2017, 38, 226-256
13. Ciocca, D.R.; Calderwood, S.K. Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005, 10, 86-103
14. Haslbeck, M.; Vierling, E. A first line of stress defense: Small heat shock proteins and their function in protein homeostasis. J. Mol. Biol. 2015, 427, 1537-1548
15. Bepperling, A.; Alte, F.; Kriehuber, T.; Braun, N.; Weinkauf, S.; Groll, M.; Haslbeck, M.; Buchner, J. Alternative bacterial two-component small heat shock protein systems. Proc. Natl. Acad. Sci. USA 2012, 109, 20407-20412
16. Kampinga, H.H.; Hageman, J.; Vos, M.J.; Kubota, H.; Tanguay, R.M.; Bruford, E.A.; Haslbeck, M.; Buchner, J. Guidelines for the nomenclature of the human heat shock proteins. Cell Stress Chaperones 2009, 14, 105-111
17. Shamovsky, I.; Nudler, E. New insights into the mechanism of heat shock response activation. Cell. Mol. Life Sci. CMLS 2008, 65, 855-861
18. Garrido, C.; Brunet, M.; Didelot, C.; Zermati, Y.; Schmitt, E.; Kroemer, G. Heat shock proteins 27 and 70: Anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006, 5, 2592-2601
19. Green, M.; Schuetz, T.J.; Sullivan, E.K.; Kingston, R.E. A heat shock-responsive domain of human HSF1 that regulates transcription activation domain function. Mol. Cell. Biol. 1995, 15, 3354-3362
20. Nakai, A.; Tanabe, M.; Kawazoe, Y.; Inazawa, J.; Morimoto, R.I.; Nagata, K. HSF4, a new member of the human heat shock factor family which lacks properties of a transcriptional activator. Mol. Cell. Biol. 1997, 17, 469-481
21. Sistonen, L.; Sarge, K.D.; Morimoto, R.I. Human heat shock factors 1 and 2 are differentially activated and can synergistically induce hsp70 gene transcription. Mol. Cell. Biol. 1994, 14, 2087-2099
22. Akerfelt, M.; Morimoto, R.I.; Sistonen, L. Heat shock factors: Integrators of cell stress, development and lifespan. Nat. Rev. Mol. Cell Biol. 2010, 11, 545-555
23. Whitesell, L.; Lindquist, S. Inhibiting the transcription factor HSF1 as an anticancer strategy. Expert Opin. Ther. Target 2009, 13, 469-478
24. De Maio, A. Heat shock proteins: Facts, thoughts, and dreams. Shock 1999, 11, 1-12
25. Fan, G.C. Role of Heat Shock Proteins in Stem Cell Behavior. Prog. Mol. Biol. Trans. Sci. 2012, 111, 305-322.
26. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674
27. Neckers, L.; Workman, P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin. Cancer Res. 2012, 18, 64-76
28. Xia, Y.; Rocchi, P.; Iovanna, J.L.; Peng, L. Targeting heat shock response pathways to treat pancreatic cancer. Drug Discov. Today 2012, 17, 35-43
29. Kopecek, P.; Altmannova, K.; Weigl, E. Stress proteins: Nomenclature, division and functions. In Biomedical Papers; Medical Faculty of the University Palacky Olomouc Czechoslovakia: Olomouc, Czech Republic, 2001; Volume 145, pp. 39-47.
30. Hendrick, J.P.; Hartl, F.U. Molecular chaperone functions of heat-shock proteins. Annu. Rev. Biochem. 1993, 62, 349-384
31. Sreedhar, A.S.; Kalmar, E.; Csermely, P.; Shen, Y.F. Hsp90 isoforms: Functions, expression and clinical importance. FEBS. Lett. 2004, 562, 11-15
32. Fuller, K.J.; Issels, R.D.; Slosman, D.O.; Guillet, J.G.; Soussi, T.; Polla, B.S. Cancer and the heat shock response. Eur. J. Cancer 1994, 30, 1884-1891
33. Morimoto, R.I. Heat shock: The role of transient inducible responses in cell damage, transformation, and differentiation. Cancer Cells 1991, 3, 295-301
34. Ciocca, D.R.; Rozados, V.R.; Cuello Carrion, F.D.; Gervasoni, S.I.; Matar, P.; Scharovsky, O.G. Hsp25 and Hsp70 in rodent tumors treated with doxorubicin and lovastatin. Cell Stress Chaperones 2003, 8, 26-36
35. Nylandsted, J.; Rohde, M.; Brand, K.; Bastholm, L.; Elling, F.; Jaattela, M. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses, Bcl-2. Proc. Natl. Acad. Sci. USA 2000, 97, 7871-7876
36. Volloch, V.Z.; Sherman, M.Y. Oncogenic potential of Hsp72. Oncogene 1999, 18, 3648-3651
37. Hoang, A.T.; Huang, J.; Rudra-Ganguly, N.; Zheng, J.; Powell, W.C.; Rabindran, S.K.; Rabindran, C.W.; Pradip, R.B. A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. Am. J. Pathol. 2000, 156, 857-864
38. Wang, Y.; Theriault, J.R.; He, H.; Gong, J.; Calderwood, S.K. Expression of a dominant negative heat shock factor-1 construct inhibits aneuploidy in prostate carcinoma cells. J. Biol. Chem. 2004, 279, 32651-32659
39. Cho, W.C. Contribution of oncoproteomics to cancer biomarker discovery. Mol. Cancer 2007, 6, 25
40. Khalil, A.A.; Kabapy, N.F.; Deraz, S.F.; Smith, C. Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets? Biochim. Biophys. Acta 2011, 1816, 89-104
41. Castro, G.N.; Cayado-Gutierrez, N.; Moncalero, V.L.; Lima, P.; De Angelis, R.L.; Chavez, V.; Cuello-Carrión, F.D.; Ciocca, D.R. Hsp27 (HSPB1): A possible surrogate molecular marker for loss of heterozygosity (LOH) of chromosome 1p in oligodendrogliomas but not in astrocytomas. Cell Stress Chaperones 2012, 17, 779-790
42. Ciocca, D.R.; Oesterreich, S.; Chamness, G.C.; McGuire, W.L.; Fuqua, S.A. Biological and clinical implications of heat shock protein 27,000 (Hsp27): A review. J. Natl. Cancer Inst. 1993, 85, 1558-1570
43. Conroy, S.E.; Latchman, D.S. Do heat shock proteins have a role in breast cancer? Br. J. Cancer 1996, 74, 717-721
44. Duval, A.; Olaru, D.; Campos, L.; Flandrin, P.; Nadal, N.; Guyotat, D. Expression and prognostic significance of heat-shock proteins in myelodysplastic syndromes. Haematologica 2006, 91, 713-714
45. Nagata, Y.; Kudo, M.; Nagai, T.; Watanabe, T.; Kawasaki, M.; Asakuma, Y.; Hagiwara, S.; Nishida, N.; Matsui, S.; Kashida, H. Heat shock protein 27 expression is inversely correlated with atrophic gastritis and intraepithelial neoplasia. Dig. Dis. Sci. 2013, 58, 381-388
46. Roman, E.; Lunde, M.L.; Miron, T.; Warnakulasauriya, S.; Johannessen, A.C.; Vasstrand, E.N.; Ibrahim, S.O. Analysis of protein expression profile of oral squamous cell carcinoma by MALDI-TOF-MS. Anticancer Res. 2013, 33, 837-845
47. Thomas, X.; Campos, L.; Mounier, C.; Cornillon, J.; Flandrin, P.; Le, Q.H.; Piselli, S.; Guyotat, D. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia. Leuk. Res. 2005, 29, 1049-1058
48. Wang, S.; Yang, S.; Vlantis, A.C.; Liu, S.Y.; Ng, E.K.; Chan, A.B.; Wu, J.; Du, J.; Wei, W.; Liu, X. Expression of Antioxidant Molecules and Heat Shock Protein 27 in Thyroid Tumors. J. Cell. Biochem. 2016, 117, 2473-2481
49. Wong, H.R.; Wispe, J.R. The stress response and the lung. Am. J. Physiol. 1997, 273, L1-L9
50. Yang, L.; Cao, L.; Yang, M.; Tang, D.; Kang, R.; Min, X.; Zhu, S.; Yu, Y. Hsp27: A novel therapeutic target for pediatric M4/M5 acute myeloid leukemia. Oncol. Rep. 2013, 29, 1459-1466
51. Zanini, C.; Pulera, F.; Carta, F.; Giribaldi, G.; Mandili, G.; Maule, M.M.; Forni, M.; Turrini, F. Proteomic identification of heat shock protein 27 as a differentiation and prognostic marker in neuroblastoma but not in Ewing’s sarcoma. Virchows Arch. 2008, 452, 157-167
52. Assimakopoulou, M. Human meningiomas: Immunohistochemical localization of progesterone receptor and heat shock protein 27 and absence of estrogen receptor and PS2. Cancer Detect. Prev. 2000, 24, 163-168
53. Yu, Z.; Zhi, J.; Peng, X.; Zhong, X.; Xu, A. Clinical significance of HSP27 expression in colorectal cancer. Mol. Med. Rep. 2010, 3, 953-958
54. Tweedle, E.M.; Khattak, I.; Ang, C.W.; Nedjadi, T.; Jenkins, R.; Park, B.K.; Kalirai, H.; Dodson, A.; Azadeh, B.; Terlizzo, M.; et al. Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut 2010, 59, 1501-1510
55. Bauer, K.; Nitsche, U.; Slotta-Huspenina, J.; Drecoll, E.; von Weyhern, C.H.; Rosenberg, R.; Hofler, H.; Langer, R. High HSP27 and HSP70 expression levels are independent adverse prognostic factors in primary resected colon cancer. Cell Oncol. 2012, 35, 197-205
56. Miyake, H.; Muramaki, M.; Kurahashi, T.; Yamanaka, K.; Hara, I.; Fujisawa, M. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer. Anti Cancer Res. 2006, 26, 1583-1587.
57. Daniels, G.A.; Sanchez-Perez, L.; Diaz, R.M.; Kottke, T.; Thompson, J.; Lai, M.; Kalirai, H.; Dodson, A.; Azadeh, B.; Terlizzo, M. A simple method to cure established tumors by inflammatory killing of normal cells. Nat. Biotechnol. 2004, 22, 1125-1132
58. Hata, M.; Ohtsuka, K. Characterization of HSE sequences in human Hsp40 gene: Structural and promoter analysis. Biochim. Biophys. Acta 1998, 1397, 43-55
59. Sterrenberg, J.N.; Blatch, G.L.; Edkins, A.L. Human DNAJ in cancer and stem cells. Cancer Lett. 2011, 312, 129-142
60. Castle, P.E.; Ashfaq, R.; Ansari, F.; Muller, C.Y. Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. Cancer Lett. 2005, 229, 245-252
61. Isomoto, H.; Oka, M.; Yano, Y.; Kanazawa, Y.; Soda, H.; Terada, R.; Yasutake, T.; Nakayama, T.; Shikuwa, S.; Takeshima, F. Expression of heat shock protein (Hsp) 70 and Hsp 40 in gastric cancer. Cancer Lett. 2003, 198, 219-228
62. Kanazawa, Y.; Isomoto, H.; Oka, M.; Yano, Y.; Soda, H.; Shikuwa, S.; Takeshima, F.; Omagari, K.; Mizuta, Y.; Murase, K.; et al. Expression of heat shock protein (Hsp) 70 and Hsp 40 in colorectal cancer. Med. Oncol. 2003, 20, 157-164
63. Oka, M.; Sato, S.; Soda, H.; Fukuda, M.; Kawabata, S.; Nakatomi, K.; Shiozawa, K.; Nakamura, Y.; Ohtsuka, K.; Kohno, S. Autoantibody to heat shock protein Hsp40 in sera of lung cancer patients. Jpn. J. Cancer Res. Gann 2001, 92, 316-320
64. Mosser, D.D.; Morimoto, R.I. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23, 2907-2918
65. Chen, J.S.; Coustan-Smith, E.; Suzuki, T.; Neale, G.A.; Mihara, K.; Pui, C.H.; Campana, D. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001, 97, 2115-2120
66. Trinh, D.L.; Elwi, A.N.; Kim, S.W. Direct interaction between p53 and Tid1 proteins affects p53 mitochondrial localization and apoptosis. Oncotarget 2010, 1, 396-404
67. Chen, C.Y.; Chiou, S.H.; Huang, C.Y.; Jan, C.I.; Lin, S.C.; Hu, W.Y.; Chou, S.H.; Liu, C.J.; Lo, J.F. Tid1 functions as a tumour suppressor in head and neck squamous cell carcinoma. J. Pathol. 2009, 219, 347-355
68. Mitra, A.; Fillmore, R.A.; Metge, B.J.; Rajesh, M.; Xi, Y.; King, J.; Ju, J.; Pannell, L.; Shevde, L.A.; Samant, R.S. Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Res. 2008, 10, R22
69. Mitra, A.; Menezes, M.E.; Shevde, L.A.; Samant, R.S. DNAJB6 induces degradation of beta-catenin and causes partial reversal of mesenchymal phenotype. J. Biol. Chem. 2010, 285, 24686-24694
70. Liu, T.; Jiang, W.; Han, D.; Yu, L. DNAJC25 is downregulated in hepatocellular carcinoma and is a novel tumor suppressor gene. Oncol. Lett. 2012, 4, 1274-1280
71. Mahoney, S.E.; Yao, Z.; Keyes, C.C.; Tapscott, S.J.; Diede, S.J. Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. Epigenetics 2012, 7, 400-408
72. De Bessa, S.A.; Salaorni, S.; Patrao, D.F.; Neto, M.M.; Brentani, M.M.; Nagai, M.A. JDP1 (DNAJC12/Hsp40) expression in breast cancer and its association with estrogen receptor status. Int. J. Mol. Med. 2006, 17, 363-367
73. Pang, Q.; Christianson, T.A.; Keeble, W.; Koretsky, T.; Bagby, G.C. The anti-apoptotic function of Hsp70 in the interferon-inducible double-stranded RNA-dependent protein kinase-mediated death signaling pathway requires the Fanconi anemia protein FANCC. J. Biol. Chem. 2002, 277, 49638-49643
74. Ghosh, J.C.; Dohi, T.; Kang, B.H.; Altieri, D.C. Hsp60 regulation of tumor cell apoptosis. J. Biol. Chem. 2008, 283, 5188-5194
75. Hwang, Y.J.; Lee, S.P.; Kim, S.Y.; Choi, Y.H.; Kim, M.J.; Lee, C.H.; Lee, J.Y.; Kim, D.Y. Expression of heat shock protein 60 kDa is upregulated in cervical cancer. Yonsei Med. J. 2009, 50, 399-406
76. Castilla, C.; Congregado, B.; Conde, J.M.; Medina, R.; Torrubia, F.J.; Japon, M.A.; Saez, C. Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer. Urology 2010, 76, 1017.e1-1017.e6
77. Hamelin, C.; Cornut, E.; Poirier, F.; Pons, S.; Beaulieu, C.; Charrier, J.P.; Haidous, H.; Cotte, E.; Lambert, C.; Piard, F.; et al. Identification and verification of heat shock protein 60 as a potential serum marker for colorectal cancer. FEBS J. 2011, 278, 4845-4859
78. Giaginis, C.; Daskalopoulou, S.S.; Vgenopoulou, S.; Sfiniadakis, I.; Kouraklis, G.; Theocharis, S.E. Heat Shock Protein-27, -60 and -90 expression in gastric cancer: Association with clinicopathological variables and patient survival. BMC Gastroenterol. 2009, 9, 14
79. Desmetz, C.; Bibeau, F.; Boissiere, F.; Bellet, V.; Rouanet, P.; Maudelonde, T.; Mange, A.; Solassol, J. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. J. Proteome Res. 2008, 7, 3830-3837
80. Hjerpe, E.; Egyhazi, S.; Carlson, J.; Stolt, M.F.; Schedvins, K.; Johansson, H.; Shoshan, M.; Avall-Lundqvist, E. HSP60 predicts survival in advanced serous ovarian cancer. International journal of gynecological cancer. Int. J. Gynecol. Cancer 2013, 23, 448-455.
81. Abdalla, M.A.; Haj-Ahmad, Y. Promising Urinary Protein Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients. J. Cancer 2012, 3, 390-403
82. Abu-Hadid, M.; Wilkes, J.D.; Elakawi, Z.; Pendyala, L.; Perez, R.P. Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines. Cancer Lett. 1997, 119, 63-70.
83. Tsai, Y.P.; Yang, M.H.; Huang, C.H.; Chang, S.Y.; Chen, P.M.; Liu, C.J.; Teng, S.C.; Wu, K.J. Interaction between HSP60 and beta-catenin promotes metastasis. Carcinogenesis 2009, 30, 1049-1057
84. Rerole, A.L.; Jego, G.; Garrido, C. Hsp70: Anti-apoptotic and tumorigenic protein. Methods Mol. Biol. 2011, 787, 205-230
85. Sherman, M.Y.; Gabai, V.L. Hsp70 in cancer: Back to the future. Oncogene 2015, 34, 4153-4161
86. Murphy, M.E. The HSP70 family and cancer. Carcinogenesis 2013, 34, 1181-1188
87. Wang, X.; Wang, Q.; Lin, H. Correlation between clinicopathology and expression of heat shock protein 72 and glycoprotein 96 in human esophageal squamous cell carcinoma. Clin. Dev. Immunol. 2010, 2010, 212537
88. Cai, M.B.; Wang, X.P.; Zhang, J.X.; Han, H.Q.; Liu, C.C.; Bei, J.X.; Peng, R.J.; Liang, Y.; Feng, Q.S.; Wang, H.Y.; et al. Expression of heat shock protein 70 in nasopharyngeal carcinomas: Different expression patterns correlate with distinct clinical prognosis. J. Trans. Med. 2012, 10, 96
89. Moghanibashi, M.; Rastgar Jazii, F.; Soheili, Z.S.; Zare, M.; Karkhane, A.; Parivar, K.; Mohamadynejad, P. Esophageal cancer alters the expression of nuclear pore complex binding protein, Hsc70 and eIF5A-1. Funct. Integr. Genom. 2013, 13, 253-260
90. Bakkenist, C.J.; Koreth, J.; Williams, C.S.; Hunt, N.C.; McGee, J.O. Heat shock cognate 70 mutations in sporadic breast carcinoma. Cancer Res. 1999, 59, 4219-4221
91. Chen, J.; Liu, W.B.; Jia, W.D.; Xu, G.L.; Ma, J.L.; Huang, M.; Deng, Y.R.; Li, J.S. Overexpression of Mortalin in hepatocellular carcinoma and its relationship with angiogenesis and epithelial to mesenchymal transition. Int. J. Oncol. 2014, 44, 247-255
92. Jin, H.; Ji, M.; Chen, L.; Liu, Q.; Che, S.; Xu, M.; Lin, Z. The clinicopathological significance of Mortalin overexpression in invasive ductal carcinoma of breast. J. Exp. Clin. Cancer Res. 2016, 35, 42
93. Yi, X.; Luk, J.M.; Lee, N.P.; Peng, J.; Leng, X.; Guan, X.Y.; Lau, G.K.; Beretta, L.; Fan, S.T. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol. Cell. Proteom. 2008, 7, 315-325
94. Ando, K.; Oki, E.; Zhao, Y.; Ikawa-Yoshida, A.; Kitao, H.; Saeki, H.; Kimura, Y.; Ida, S.; Morita, M.; Kusumoto, T.; et al. Mortalin is a prognostic factor of gastric cancer with normal p53 function. Gastric Cancer 2014, 17, 255-262
95. Rozenberg, P.; Kocsis, J.; Saar, M.; Prohaszka, Z.; Fust, G.; Fishelson, Z. Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer. Int. J. Cancer 2013, 133, 514-518
96. Yerushalmi, R.; Raiter, A.; Nalbandyan, K.; Hardy, B. Cell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancer. Oncol. Lett. 2015, 10, 2149-2155
97. Burrows, F.; Zhang, H.; Kamal, A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004, 3, 1530-1536
98. Patel, K.; Wen, J.; Magliocca, K.; Muller, S.; Liu, Y.; Chen, Z.G.; Saba, N.; Diaz, R. Heat shock protein 90 (HSP90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of chemoradiation. Cancer Chemother. Pharmacol. 2014, 74, 1015-1022
99. Huang, T.; Chen, S.; Han, H.; Li, H.; Huang, Z.; Zhang, J.; Yin, Q.; Wang, X.; Ma, X.; Dai, P.; et al. Expression of, Hsp90alpha and cyclin, B1 were related to prognosis of esophageal squamous cell carcinoma and keratin pearl formation. Int. J. Clin. Exp. Pathol. 2014, 7, 1544-1552
100. McCarthy, M.M.; Pick, E.; Kluger, Y.; Gould-Rothberg, B.; Lazova, R.; Camp, R.L.; Rimm, D.L.; Kluger, H.M. HSP90 as a marker of progression in melanoma. Ann. Oncol. 2008, 19, 590-594
101. Tian, W.L.; He, F.; Fu, X.; Lin, J.T.; Tang, P.; Huang, Y.M.; Guo, R.; Sun, L. High expression of heat shock protein 90 alpha and its significance in human acute leukemia cells. Gene 2014, 542, 122-128
102. Zackova, M.; Mouckova, D.; Lopotova, T.; Ondrackova, Z.; Klamova, H.; Moravcova, J. Hsp90—A potential prognostic marker in CML. Blood Cells Mol. Dis. 2013, 50, 184-189
103. Alexiou, G.A.; Vartholomatos, G.; Stefanaki, K.; Patereli, A.; Dova, L.; Karamoutsios, A.; Lallas, G.; Sfakianos, G.; Moschovi, M.; Prodromou, N. Expression of heat shock proteins in medulloblastoma. J. Neurosurg. Pediatr. 2013, 12, 452-457
104. Zagouri, F.; Sergentanis, T.; Nonni, A.; Papadimitriou, C.; Pazaiti, A.; Michalopoulos, N.V.; Safioleas, P.; Lazaris, A.; Theodoropoulos, G.; Patsouris, E.; et al. Decreased Hsp90 expression in infiltrative lobular carcinoma: An immunohistochemical study. BMC Cancer 2010, 10, 409
105. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70
106. Workman, P.; Burrows, F.; Neckers, L.; Rosen, N. Drugging the cancer chaperone, HSP90: Combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N. Y. Acad. Sci. 2007, 1113, 202-216
107. Chan, A.T. Turning up the heat on colorectal cancer. Nat. Med. 2011, 17, 1186-1188
108. Duval, A.; Collura, A.; Berthenet, K.; Lagrange, A.; Garrido, C. Microsatellite instability in colorectal cancer: Time to stop hiding! Oncotarget 2011, 2, 826-827
109. Gotoh, K.; Nonoguchi, K.; Higashitsuji, H.; Kaneko, Y.; Sakurai, T.; Sumitomo, Y.; Itoh, K.; Subjeck, J.R.; Fujita, J. Apg-2 has a chaperone-like activity similar to Hsp110 and is overexpressed in hepatocellular carcinomas. FEBS Lett. 2004, 560, 19-24
110. Kim, J.H.; Kim, K.J.; Rhee, Y.Y.; Oh, S.; Cho, N.Y.; Lee, H.S.; Kang, G.H. Expression status of wild-type HSP110 correlates with HSP110 T17 deletion size and patient prognosis in microsatellite-unstable colorectal cancer. Mod. Pathol. 2014, 27, 443-453
111. Kimura, A.; Ogata, K.; Altan, B.; Yokobori, T.; Ide, M.; Mochiki, E.; Toyomasu, Y.; Kogure, N.; Yanoma, T.; Suzuki, M.; et al. Nuclear heat shock protein 110 expression is associated with poor prognosis and chemotherapy resistance in gastric cancer. Oncotarget 2016, 7, 18415-18423
112. Ullmann, R.; Morbini, P.; Halbwedl, I.; Bongiovanni, M.; Gogg-Kammerer, M.; Papotti, M.; Gabor, S.; Renner, H.; Popper, H.H. Protein expression profiles in adenocarcinomas and squamous cell carcinomas of the lung generated using tissue microarrays. J. Pathol. 2004, 203, 798-807
113. Fu, Y.; Lee, A.S. Glucose regulated proteins in cancer progression drug resistance and immunotherapy. Cancer Biol. Ther. 2006, 5, 741-744
114. Manjili, M.H.; Park, J.E.; Facciponte, J.G.; Wang, X.Y.; Subjeck, J.R. Immunoadjuvant chaperone GRP170, induces ‘danger signals’ upon interaction with dendritic cells. Immunol. Cell Biol. 2006, 84, 203-208
115. Dai, C.; Sampson, S.B. HSF1: Guardian of Proteostasis in Cancer. Trends Cell Biol. 2016, 26, 17-28
116. Jiang, S.; Tu, K.; Fu, Q.; Schmitt, D.C.; Zhou, L.; Lu, N.; Zhao, Y. Multifaceted roles of HSF1 in cancer. Tumour Biol. 2015, 36, 4923-4931
117. Santagata, S.; Hu, R.; Lin, N.U.; Mendillo, M.L.; Collins, L.C.; Hankinson, S.E.; Schnitt, S.J.; Whitesell, L.; Tamimi, R.M.; Lindquist, S.; et al. High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 18378-18383
118. Mendillo, M.L.; Santagata, S.; Koeva, M.; Bell, G.W.; Hu, R.; Tamimi, R.M.; Fraenkel, E.; Ince, T.A.; Whitesell, L.; Lindquist, S. HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. Cell 2012, 150, 549-562
119. Engerud, H.; Tangen, I.L.; Berg, A.; Kusonmano, K.; Halle, M.K.; Oyan, A.M.; Kalland, K.H.; Stefansson, I.; Trovik, J.; Salvesen, H.B.; et al. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. Br. J. Cancer 2014, 111, 78-84
120. Ishiwata, J.; Kasamatsu, A.; Sakuma, K.; Iyoda, M.; Yamatoji, M.; Usukura, K.; Ishige, S.; Shimizu, T.; Yamano, Y.; Ogawara, K.; et al. State of heat shock factor 1 expression as a putative diagnostic marker for oral squamous cell carcinoma. Int. J. Oncol. 2012, 40, 47-52
121. Landriscina, M.; Amoroso, M.R.; Piscazzi, A.; Esposito, F. Heat shock proteins cell survival and drug resistance: The mitochondrial chaperone TRAP1 a potential novel target for ovarian cancer therapy. Gynecol. Oncol. 2010, 117, 177-182
122. Freshney, N.W.; Rawlinson, L.; Guesdon, F.; Jones, E.; Cowley, S.; Hsuan, J.; Saklatvala, J. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 1994, 78, 1039-1049
123. Vidyasagar, A.; Wilson, N.A.; Djamali, A. Heat shock protein 27 (HSP27): Biomarker of disease and therapeutic target. Fibrogenes. Tissue Repair 2012, 5, 7
124. Lelj-Garolla, B.; Mauk, A.G. Self-association and chaperone activity of Hsp27 are thermally activated. J. Biol. Chem. 2006, 281, 8169-8174
125. Guay, J.; Lambert, H.; Gingras-Breton, G.; Lavoie, J.N.; Huot, J.; Landry, J. Regulation of actin filament dynamics by p38 map kinase-mediated phosphorylation of heat shock protein 27. J. Cell Sci. 1997, 110, 357-368
126. Lentze, N.; Narberhaus, F. Detection of oligomerisation and substrate recognition sites of small heat shock proteins by peptide arrays. Biochem. Biophys. Res. Commun. 2004, 325, 401-407
127. Hayes, D.; Napoli, V.; Mazurkie, A.; Stafford, W.F.; Graceffa, P. Phosphorylation dependence of Hsp27 multimeric size and molecular chaperone function. J. Biol. Chem. 2009, 284, 18801-18807
128. Rogalla, T.; Ehrnsperger, M.; Preville, X.; Kotlyarov, A.; Lutsch, G.; Ducasse, C.; Paul, C.; Wieske, M.; Arrigo, A.P.; Buchner, J.; et al. Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J. Biol. Chem. 1999, 274, 18947-18956
129. Arrigo, A.P.; Gibert, B. HspB1 dynamic phospho-oligomeric structure dependent interactome as cancer therapeutic target. Curr. Mol. Med. 2012, 12, 1151-1163
130. Cayado-Gutierrez, N.; Moncalero, V.L.; Rosales, E.M.; Beron, W.; Salvatierra, E.E.; Alvarez-Olmedo, D.; Radrizzani, M.; Ciocca, D.R. Downregulation of Hsp27 (HSPB1) in MCF-7 human breast cancer cells induces upregulation of PTEN. Cell Stress Chaperones 2013, 18, 243-249
131. Gibert, B.; Simon, S.; Dimitrova, V.; Diaz-Latoud, C.; Arrigo, A.P. Peptide aptamers: Tools to negatively or positively modulate HSPB1(27) function. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2013, 368, 20120075
132. Xu, L.; Chen, S.; Bergan, R.C. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006, 25, 2987-2998
133. Zhao, M.; Shen, F.; Yin, Y.X.; Yang, Y.Y.; Xiang, D.J.; Chen, Q. Increased expression of heat shock protein 27 correlates with peritoneal metastasis in epithelial ovarian cancer. Reprod. Sci. 2012, 19, 748-753
134. Yu, L.; Yuan, X.; Wang, D.; Barakat, B.; Williams, E.D.; Hannigan, G.E. Selective regulation of p38beta protein and signaling by integrin-linked kinase mediates bladder cancer cell migration. Oncogene 2014, 33, 690-701
135. O’Callaghan-Sunol, C.; Gabai, V.L.; Sherman, M.Y. Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res. 2007, 67, 11779-11788
136. Zhang, S.; Hu, Y.; Huang, Y.; Xu, H.; Wu, G.; Dai, H. Heat shock protein 27 promotes cell proliferation through activator protein-1 in lung cancer. Oncol. Lett. 2015, 9, 2572-2576
137. Bruey, J.M.; Ducasse, C.; Bonniaud, P.; Ravagnan, L.; Susin, S.A.; Diaz-Latoud, C.; Gurbuxani, S.; Arrigo, A.P.; Kroemer, G.; Solary, E.; et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2000, 2, 645-652
138. Paul, C.; Manero, F.; Gonin, S.; Kretz-Remy, C.; Virot, S.; Arrigo, A.P. Hsp27 as a negative regulator of cytochrome C release. Mol. Cell. Biol. 2002, 22, 816-834
139. Lin, S.P.; Lee, Y.T.; Wang, J.Y.; Miller, S.A.; Chiou, S.H.; Hung, M.C.; Hung, S.C. Survival of cancer stem cells under hypoxia and serum depletion via decrease in PP2A activity and activation of p38-MAPKAPK2-Hsp27. PLoS ONE 2012, 7, e49605
140. Edwards, K.M.; Munger, K. Depletion of physiological levels of the human TID1 protein renders cancer cell lines resistant to apoptosis mediated by multiple exogenous stimuli. Oncogene 2004, 23, 8419-8431
141. Chen, C.Y.; Jan, C.I.; Lo, J.F.; Yang, S.C.; Chang, Y.L.; Pan, S.H.; Wang, W.L.; Hong, T.M.; Yang, P.C. Tid1-L inhibits EGFR signaling in lung adenocarcinoma by enhancing EGFR Ubiquitinylation and degradation. Cancer Res. 2013, 73, 4009-4019
142. Mitra, A.; Shevde, L.A.; Samant, R.S. Multi-faceted role of HSP40 in cancer. Clin. Exp. Metast. 2009, 26, 559-567
143. Syken, J.; De-Medina, T.; Munger, K. TID1 a human homolog of the, Drosophila tumor suppressor l(2)tid, encodes two mitochondrial modulators of apoptosis with opposing functions. Proc. Natl. Acad. Sci. USA 1999, 96, 8499-8504
144. Kim, S.W.; Hayashi, M.; Lo, J.F.; Fearns, C.; Xiang, R.; Lazennec, G.; Yang, Y.; Lee, J.D. Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8. Cancer Res. 2005, 65, 8784-8791
145. Kim, S.W.; Chao, T.H.; Xiang, R.; Lo, J.F.; Campbell, M.J.; Fearns, C.; Lee, J.D. Tid1 the human homologue of a, Drosophila tumor suppressor reduces the malignant activity of ErbB-2 in carcinoma cells. Cancer Res. 2004, 64, 7732-7739
146. Bae, M.K.; Jeong, J.W.; Kim, S.H.; Kim, S.Y.; Kang, H.J.; Kim, D.M.; Bae, S.K.; Yun, I.; Trentin, G.A.; Rozakis-Adcock, M.; et al. Tid-1 interacts with the von, Hippel-Lindau protein and modulates angiogenesis by destabilization of HIF-1alpha. Cancer Res. 2005, 65, 2520-2525
147. Cheng, H.; Cenciarelli, C.; Nelkin, G.; Tsan, R.; Fan, D.; Cheng-Mayer, C.; Fidler, I.J. Molecular mechanism of hTid-1 the human homolog of Drosophila tumor suppressor l(2)Tid in the regulation of NF-kappaB activity and suppression of tumor growth. Mol. Cell. Biol. 2005, 25, 44-59
148. Kurzik-Dumke, U.; Horner, M.; Czaja, J.; Nicotra, M.R.; Simiantonaki, N.; Koslowski, M.; Natali, P.G. Progression of colorectal cancers correlates with overexpression and loss of polarization of expression of the htid-1 tumor suppressor. Int. J. Mol. Med. 2008, 21, 19-31
149. Wang, C.C.; Tsai, M.F.; Hong, T.M.; Chang, G.C.; Chen, C.Y.; Yang, W.M.; Chen, J.J.; Yang, P.C. The transcriptional factor YY1 upregulates the novel invasion suppressor HLJ1 expression and inhibits cancer cell invasion. Oncogene 2005, 24, 4081-4093
150. Tsai, M.F.; Wang, C.C.; Chang, G.C.; Chen, C.Y.; Chen, H.Y.; Cheng, C.L.; Yang, Y.P.; Wu, C.Y.; Shih, F.Y.; Liu, C.C.; et al. A new tumor suppressor, DnaJ-like heat shock protein, HLJ1 and survival of patients with non-small-cell lung carcinoma. J. Natl. Cancer Inst. 2006, 98, 825-838
151. Chen, H.W.; Lee, J.Y.; Huang, J.Y.; Wang, C.C.; Chen, W.J.; Su, S.F.; Huang, C.W.; Ho, C.C.; Chen, J.J.; Tsai, M.F.; et al. Curcumin inhibits lung cancer cell invasion and metastasis through the tumor suppressor HLJ1. Cancer Res. 2008, 68, 7428-7438
152. Menezes, M.E.; Devine, D.J.; Shevde, L.A.; Samant, R.S. Dickkopf1: A tumor suppressor or metastasis promoter? Int. J. Cancer 2012, 130, 1477-1483
153. Meng, E.; Shevde, L.A.; Samant, R.S. Emerging roles and underlying molecular mechanisms of DNAJB6 in cancer. Oncotarget 2016, 7, 53984-53996
154. Yu, V.Z.; Wong, V.C.; Dai, W.; Ko, J.M.; Lam, A.K.; Chan, K.W.; Samant, R.S.; Lung, H.L.; Shuen, W.H.; Law, S.; et al. Nuclear Localization of DNAJB6 is Associated with Survival of Patients with Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer Cells. Gastroenterology 2015, 149, 1825-1836.e5
155. Wen, K.W.; Damania, B. Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHVK1. Oncogene 2010, 29, 3532-3544
156. Cui, X.; Choi, H.K.; Choi, Y.S.; Park, S.Y.; Sung, G.J.; Lee, Y.H.; Lee, J.; Jun, W.J.; Kim, K.; Choi, K.C.; et al. DNAJB1 destabilizes PDCD5 to suppress p53-mediated apoptosis. Cancer Lett. 2015, 357, 307-315
157. Nishizawa, S.; Hirohashi, Y.; Torigoe, T.; Takahashi, A.; Tamura, Y.; Mori, T.; Kanaseki, T.; Kamiguchi, K.; Asanuma, H.; Morita, R.; et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res. 2012, 72, 2844-2854
158. Yang, T.; Li, X.N.; Li, X.G.; Li, M.; Gao, P.Z. DNAJC6 promotes hepatocellular carcinoma progression through induction of epithelial-mesenchymal transition. Biochem. Biophys. Res. Commun. 2014, 455, 298-304
159. Sigler, P.B.; Xu, Z.; Rye, H.S.; Burston, S.G.; Fenton, W.A.; Horwich, A.L. Structure and function in GroEL-mediated protein folding. Annu. Rev. Biochem. 1998, 67, 581-608
160. Ohashi, S.; Atsumi, M.; Kobayashi, S. HSP60 interacts with YB-1 and affects its polysome association and subcellular localization. Biochem. Biophys. Res. Commun. 2009, 385, 545-550
161. Liffers, S.T.; Maghnouj, A.; Munding, J.B.; Jackstadt, R.; Herbrand, U.; Schulenborg, T.; Marcus, K.; Klein-Scory, S.; Schmiegel, W.; Schwarte-Waldhoff, I.; et al. Keratin 23 a novel DPC4/Smad4 target gene which binds 14-3-3epsilon. BMC Cancer 2011, 11, 137
162. Lv, L.H.; Wan, Y.L.; Lin, Y.; Zhang, W.; Yang, M.; Li, G.L.; Lin, H.M.; Shang, C.Z.; Chen, Y.J.; Min, J. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J. Biol. Chem. 2012, 287, 15874-15885
163. Chaiwatanasirikul, K.A.; Sala, A. The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60. Cell Death Dis. 2011, 2, e219
164. Ghosh, J.C.; Siegelin, M.D.; Dohi, T.; Altieri, D.C. Heat shock protein 60 regulation of the mitochondrial permeability transition pore in tumor cells. Cancer Res. 2010, 70, 8988-8993
165. Gotoh, T.; Terada, K.; Oyadomari, S.; Mori, M. Hsp70-DnaJ chaperone pair prevents nitric oxideand CHOP-induced apoptosis by inhibiting translocation of Bax to mitochondria. Cell Death Differ. 2004, 11, 390-402
166. Stankiewicz, A.R.; Lachapelle, G.; Foo, C.P.; Radicioni, S.M.; Mosser, D.D. Hsp70 inhibits heat-induced apoptosis upstream of mitochondria by preventing bax translocation. J. Biol. Chem. 2005, 280, 38729-38739
167. Saleh, A.; Srinivasula, S.M.; Balkir, L.; Robbins, P.D.; Alnemri, E.S. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat. Cell Biol. 2000, 2, 476-483
168. Guo, F.; Sigua, C.; Bali, P.; George, P.; Fiskus, W.; Scuto, A.; Annavarapu, S.; Mouttaki, A.; Sondarva, G.; Wei, S.; et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood 2005, 105, 1246-1255
169. Gabai, V.L.; Meriin, A.B.; Mosser, D.D.; Caron, A.W.; Rits, S.; Shifrin, V.I.; Sherman, M.Y. Hsp70 prevents activation of stress kinases. A novel pathway of cellular thermotolerance. J. Biol. Chem. 1997, 272, 18033-18037
170. Mosser, D.D.; Caron, A.W.; Bourget, L.; Denis-Larose, C.; Massie, B. Role of the human heat shock protein hsp70 in protection against stress-induced apoptosis. Mol. Cell. Biol. 1997, 17, 5317-5327
171. Yaglom, J.; O’Callaghan-Sunol, C.; Gabai, V.; Sherman, M.Y. Inactivation of dual-specificity phosphatases is involved in the regulation of extracellular signal-regulated kinases by heat shock and hsp72. Mol. Cell. Biol. 2003, 23, 3813-3824
172. Ravagnan, L.; Gurbuxani, S.; Susin, S.A.; Maisse, C.; Daugas, E.; Zamzami, N.; Mak, T.; Jaattela, M.; Penninger, J.M.; Garrido, C.; et al. Heat-shock protein 70 antagonizes apoptosis-inducing factor. Nat. Cell Biol. 2001, 3, 839-843
173. Yaglom, J.A.; Gabai, V.L.; Sherman, M.Y. High levels of heat shock protein Hsp72 in cancer cells suppress default senescence pathways. Cancer Res. 2007, 67, 2373-2381
174. Colvin, T.A.; Gabai, V.L.; Gong, J.; Calderwood, S.K.; Li, H.; Gummuluru, S.; Matchuk, O.N.; Smirnova, S.G.; Orlova, N.V.; Zamulaeva, I.A.; et al. Hsp70-Bag3 interactions regulate cancer-related signaling networks. Cancer Res. 2014, 74, 4731-4740
175. Gabai, V.L.; Yaglom, J.A.; Waldman, T.; Sherman, M.Y. Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells. Mol. Cell. Biol. 2009, 29, 559-569
176. Daugaard, M.; Kirkegaard-Sorensen, T.; Ostenfeld, M.S.; Aaboe, M.; Hoyer-Hansen, M.; Orntoft, T.F.; Rohde, M.; Jaattela, M. Lens epithelium-derived growth factor is an Hsp70-2 regulated guardian of lysosomal stability in human cancer. Cancer Res. 2007, 67, 2559-2567
177. Kirkegaard, T.; Roth, A.G.; Petersen, N.H.; Mahalka, A.K.; Olsen, O.D.; Moilanen, I.; Zylicz, A.; Knudsen, J.; Sandhoff, K.; Arenz, C.; et al. Hsp70 stabilizes lysosomes and reverts Niemann-Pick disease-associated lysosomal pathology. Nature 2010, 463, 549-553
178. Nylandsted, J.; Gyrd-Hansen, M.; Danielewicz, A.; Fehrenbacher, N.; Lademann, U.; Hoyer-Hansen, M.; Weber, E.; Multhoff, G.; Rohde, M.; Jaattela, M. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J. Exp. Med. 2004, 200, 425-435
179. Leu, J.I.; Pimkina, J.; Frank, A.; Murphy, M.E.; George, D.L. A small molecule inhibitor of inducible heat shock protein 70. Mol. Cell 2009, 36, 15-27
180. Chiosis, G.; Vilenchik, M.; Kim, J.; Solit, D. Hsp90: The vulnerable chaperone. Drug Discov. Today 2004, 9, 881-888
181. Neckers, L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr. Top. Med. Chem. 2006, 6, 1163-1171
182. Workman, P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett. 2004, 206, 149-157
183. Zhang, H.; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med. 2004, 82, 488-499
184. Wang, X.Y.; Subjeck, J.R. High molecular weight stress proteins: Identification cloning and utilisation in cancer immunotherapy. Int. J. Hyperth. 2013, 29, 364-375
185. Zuo, D.; Subjeck, J.; Wang, X.Y. Unfolding the Role of Large Heat Shock Proteins: New Insights and Therapeutic Implications. Front. Immunol. 2016, 7, 75
186. Hatayama, T.; Yamagishi, N.; Minobe, E.; Sakai, K. Role of hsp105 in protection against stress-induced apoptosis in neuronal PC12 cells. Biochem. Biophys. Res. Commun. 2001, 288, 528-534
187. Hosaka, S.; Nakatsura, T.; Tsukamoto, H.; Hatayama, T.; Baba, H.; Nishimura, Y. Synthetic small interfering RNA targeting heat shock protein 105 induces apoptosis of various cancer cells both in vitro and in vivo. Cancer Sci. 2006, 97, 623-632
188. Yamagishi, N.; Ishihara, K.; Saito, Y.; Hatayama, T. Hsp105 family proteins suppress staurosporine-induced apoptosis by inhibiting the translocation of Bax to mitochondria in HeLa cells. Exp. Cell Res. 2006, 312, 3215-3223
189. Yu, N.; Kakunda, M.; Pham, V.; Lill, J.R.; Du, P.; Wongchenko, M.; Yan, Y.; Firestein, R.; Huang, X. HSP105 recruits protein phosphatase 2A to dephosphorylate beta-catenin. Mol. Cell. Biol. 2015, 35, 1390-1400
190. Dai, C.; Whitesell, L.; Rogers, A.B.; Lindquist, S. Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007, 130, 1005-1018
191. Min, J.N.; Huang, L.; Zimonjic, D.B.; Moskophidis, D.; Mivechi, N.F. Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 2007, 26, 5086-5097
192. Solimini, N.L.; Luo, J.; Elledge, S.J. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007, 130, 986-988
193. Vihervaara, A.; Sistonen, L. HSF1 at a glance. J. Cell Sci. 2014, 127, 261-266
194. Scherz-Shouval, R.; Santagata, S.; Mendillo, M.L.; Sholl, L.M.; Ben-Aharon, I.; Beck, A.H.; Dias-Santagata, D.; Koeva, M.; Stemmer, S.M.; Whitesell, L.; et al. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell 2014, 158, 564-578
195. Zhao, Y.H.; Zhou, M.; Liu, H.; Ding, Y.; Khong, H.T.; Yu, D.; Fodstad, O.; Tan, M. Upregulation of lactate dehydrogenase, A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene 2009, 28, 3689-3701
196. Stanhill, A.; Levin, V.; Hendel, A.; Shachar, I.; Kazanov, D.; Arber, N.; Kaminski, N.; Engelberg, D. Ha-ras(val12) induces HSP70b transcription via the HSE/HSF1 system, but HSP70b expression is suppressed in Ha-ras(val12)-transformed cells. Oncogene 2006, 25, 1485-1495
197. Chiang, W.C.; Ching, T.T.; Lee, H.C.; Mousigian, C.; Hsu, A.L. HSF-1 regulators DDL-1/2 link insulin-like signaling to heat-shock responses and modulation of longevity. Cell 2012, 148, 322-334
198. Bjork, J.K.; Akerfelt, M.; Joutsen, J.; Puustinen, M.C.; Cheng, F.; Sistonen, L.; Nees, M. Heat-shock factor 2 is a suppressor of prostate cancer invasion. Oncogene 2016, 35, 1770-1784
199. Chen, S.F.; Nieh, S.; Jao, S.W.; Liu, C.L.; Wu, C.H.; Chang, Y.C.; Yang, C.Y.; Lin, Y.S. Quercetin suppresses drug-resistant spheres via the p38 MAPK-Hsp27 apoptotic pathway in oral cancer cells. PLoS ONE 2012, 7, e49275
200. Gibert, B.; Hadchity, E.; Czekalla, A.; Aloy, M.T.; Colas, P.; Rodriguez-Lafrasse, C.; Arrigo, A.P.; Diaz-Latoud, C. Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. Oncogene 2011, 30, 3672-3681
201. Heinrich, J.C.; Tuukkanen, A.; Schroeder, M.; Fahrig, T.; Fahrig, R. RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J. Cancer Res. Clin. Oncol. 2011, 137, 1349-1361
202. Asaum, J.; Matsuzaki, H.; Kawasak, S.; Kuroda, M.; Takeda, Y.; Kishi, K.; Hiraki, Y. Effects of quercetin on the cell growth and the intracellular accumulation and retention of adriamycin. Anticancer Res. 2000, 20, 2477-2483
203. Elattar, T.M.; Virji, A.S. The inhibitory effect of curcumin genistein quercetin and cisplatin on the growth of oral cancer cells in vitro. Anticancer Res. 2000, 20, 1733-1738
204. Hosokawa, N.; Hirayoshi, K.; Kudo, H.; Takechi, H.; Aoike, A.; Kawai, K.; Nagata, K. Inhibition of the activation of heat shock factor in vivo and in vitro by flavonoids. Mol. Cell. Biol. 1992, 12, 3490-3498
205. Jacquemin, G.; Granci, V.; Gallouet, A.S.; Lalaoui, N.; Morle, A.; Iessi, E.; Morizot, A.; Garrido, C.; Guillaudeux, T.; Micheau, O. Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin’s lymphoma B cells. Haematologica 2012, 97, 38-46
206. Knowles, L.M.; Zigrossi, D.A.; Tauber, R.A.; Hightower, C.; Milner, J.A. Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr. Cancer 2000, 38, 116-122
207. Nagai, N.; Nakai, A.; Nagata, K. Quercetin suppresses heat shock response by down regulation of HSF1. Biochem. Biophys. Res. Commun. 1995, 208, 1099-1105
208. So, F.V.; Guthrie, N.; Chambers, A.F.; Carroll, K.K. Inhibition of proliferation of estrogen receptor-positive, MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Lett. 1997, 112, 127-133
209. Yoshida, M.; Sakai, T.; Hosokawa, N.; Marui, N.; Matsumoto, K.; Fujioka, A.; Nishino, H.; Aoike, A. The effect of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett. 1990, 260, 10-13
210. Hsu, H.S.; Lin, J.H.; Huang, W.C.; Hsu, T.W.; Su, K.; Chiou, S.H.; Tsai, Y.T.; Hung, S.C. Chemoresistance of lung cancer stemlike cells depends on activation of Hsp27. Cancer 2011, 117, 1516-1528
211. Shoskes, D.A.; Zeitlin, S.I.; Shahed, A.; Rajfer, J. Quercetin in men with category III chronic prostatitis: A preliminary prospective double-blind placebo-controlled trial. Urology 1999, 54, 960-963
212. McConnell, J.R.; McAlpine, S.R. Heat shock proteins 27, 40, and 70 as combinational and dual therapeutic cancer targets. Bioorganic Med. Chem. Lett. 2013, 23, 1923-1928
213. Fu, W.M.; Zhang, J.F.; Wang, H.; Xi, Z.C.; Wang, W.M.; Zhuang, P.; Zhu, X.; Chen, S.C.; Chan, T.M.; Leung, K.S.; et al. Heat shock protein 27 mediates the effect of 1,3,5-trihydroxy-13,13-dimethyl-2H-pyran [7,6-b] xanthone on mitochondrial apoptosis in hepatocellular carcinoma. J. Proteom. 2012, 75, 4833-4843
214. Kamada, M.; So, A.; Muramaki, M.; Rocchi, P.; Beraldi, E.; Gleave, M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol. Cancer Ther. 2007, 6, 299-308
215. Kumano, M.; Furukawa, J.; Shiota, M.; Zardan, A.; Zhang, F.; Beraldi, E.; Wiedmann, R.M.; Fazli, L.; Zoubeidi, A.; Gleave, M.E. Cotargeting stress-activated, Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer. Mol. Cancer Ther. 2012, 11, 1661-1671
216. Lelj-Garolla, B.; Kumano, M.; Beraldi, E.; Nappi, L.; Rocchi, P.; Ionescu, D.N.; Fazli, L.; Zoubeidi, A.; Gleave, M.E. Hsp27 Inhibition with OGX-427 Sensitizes Non-Small Cell Lung Cancer Cells to Erlotinib and Chemotherapy. Mol. Cancer Ther. 2015, 14, 1107-1116
217. Baylot, V.; Andrieu, C.; Katsogiannou, M.; Taieb, D.; Garcia, S.; Giusiano, S.; Acunzo, J.; Iovanna, J.; Gleave, M.; Garrido, C.; et al. OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2011, 2, e221
218. Cassel, J.A.; Ilyin, S.; McDonnell, M.E.; Reitz, A.B. Novel inhibitors of heat shock protein Hsp70-mediated luciferase refolding that bind to Dna. J. Bioorganic Med. Chem. 2012, 20, 3609-3614
219. Yokota, S.; Kitahara, M.; Nagata, K. Benzylidene lactam compound KNK437, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 2000, 60, 2942-2948
220. De La Motte Rouge, T.; Galluzzi, L.; Olaussen, K.A.; Zermati, Y.; Tasdemir, E.; Robert, T.; Ripoche, H.; Lazar, V.; Dessen, P.; Harper, F.; et al. A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007, 67, 6253-6262
221. Wong, C.S.; Wong, V.W.; Chan, C.M.; Ma, B.B.; Hui, E.P.; Wong, M.C.; Lam, M.Y.; Au, T.C.; Chan, W.H.; Cheuk, W.; et al. Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. Oncol. Rep. 2008, 20, 89-98
222. Gorska, M.; Marino Gammazza, A.; Zmijewski, M.A.; Campanella, C.; Cappello, F.; Wasiewicz, T.; Kuban-Jankowska, A.; Daca, A.; Sielicka, A.; Popowska, U.; et al. Geldanamycin-induced osteosarcoma cell death is associated with hyperacetylation and loss of mitochondrial pool of heat shock protein 60 (hsp60). PLoS ONE 2013, 8, e71135
223. Tretiakova, I.; Blaesius, D.; Maxia, L.; Wesselborg, S.; Schulze-Osthoff, K.; Cinatl, J., Jr.; Michaelis, M.; Werz, O. Myrtucommulone from, Myrtus communis induces apoptosis in cancer cells via the mitochondrial pathway involving caspase-9. Apoptosis 2008, 13, 119-131
224. Wiechmann, K.; Muller, H.; Konig, S.; Wielsch, N.; Svatos, A.; Jauch, J.; Werz, O. Mitochondrial Chaperonin HSP60 is the Apoptosis-Related Target for Myrtucommulone. Cell Chem. Biol. 2017, 24, 614-623.e6
225. Venkatesh, S.; Suzuki, C.K. HSP60 Takes a Hit: Inhibition of Mitochondrial Protein Folding. Cell Chem. Biol. 2017, 24, 543-545
226. Su, T.R.; Lin, J.J.; Chiu, C.C.; Chen, J.Y.; Su, J.H.; Cheng, Z.J.; Hwang, W.I.; Huang, H.H.; Wu, Y.J. Proteomic investigation of anti-tumor activities exerted by sinularin against A2058 melanoma cells. Electrophoresis 2012, 33, 1139-1152
227. Chang, C.L.; Hsu, Y.T.; Wu, C.C.; Yang, Y.C.; Wang, C.; Wu, T.C.; Hung, C.F. Immune mechanism of the antitumor effects generated by bortezomib. J. Immunol. 2012, 189, 3209-3220
228. Goloudina, A.R.; Demidov, O.N.; Garrido, C. Inhibition of HSP70: A challenging anti-cancer strategy. Cancer Lett. 2012, 325, 117-124
229. Powers, M.V.; Jones, K.; Barillari, C.; Westwood, I.; van Montfort, R.L.; Workman, P. Targeting HSP70: The second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 2010, 9, 1542-1550
230. Gyrd-Hansen, M.; Nylandsted, J.; Jaattela, M. Heat shock protein 70 promotes cancer cell viability by safeguarding lysosomal integrity. Cell Cycle 2004, 3, 1484-1485
231. Kaiser, M.; Kuhnl, A.; Reins, J.; Fischer, S.; Ortiz-Tanchez, J.; Schlee, C.; Mochmann, L.H.; Heesch, S.; Benlasfer, O.; Hofmann, W.K.; et al. Antileukemic activity of the, HSP70 inhibitor pifithrin-mu in acute leukemia. Blood Cancer J. 2011, 1, e28
232. Nadeau, K.; Nadler, S.G.; Saulnier, M.; Tepper, M.A.; Walsh, C.T. Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry 1994, 33, 2561-2567
233. Rodina, A.; Vilenchik, M.; Moulick, K.; Aguirre, J.; Kim, J.; Chiang, A.; Litz, J.; Clement, C.C.; Kang, Y.; She, Y.; et al. Selective compounds define, Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat. Chem. Biol. 2007, 3, 498-507
234. Whetstone, H.; Lingwood, C. 3’Sulfogalactolipid binding specifically inhibits Hsp70 ATPase activity in vitro. Biochemistry 2003, 42, 1611-1617
235. Braunstein, M.J.; Scott, S.S.; Scott, C.M.; Behrman, S.; Walter, P.; Wipf, P.; Coplan, J.D.; Chrico, W.; Joseph, D.; Brodsky, J.L.; et al. Antimyeloma Effects of the Heat Shock Protein 70 Molecular Chaperone Inhibitor MAL3-101. J. Oncol. 2011, 2011, 232037
236. Massey, A.J.; Williamson, D.S.; Browne, H.; Murray, J.B.; Dokurno, P.; Shaw, T.; et al. A novel small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells. Cancer Chemother. Pharmacol. 2010, 66, 535-545
237. Chatterjee, M.; Andrulis, M.; Stuhmer, T.; Muller, E.; Hofmann, C.; Steinbrunn, T.; Heimberger, T.; Schraud, H.; Kressmann, S.; Einsele, H.; et al. The PI3K/Akt signaling pathway regulates the expression of Hsp70 which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 2013, 98, 1132-1141
238. Jinwal, U.K.; Miyata, Y.; Koren, J., 3rd; Jones, J.R.; Trotter, J.H.; Chang, L.; O'Leary, J.; Morgan, D.; Lee, D.C.; Shults, C.L.; et al. Chemical manipulation of hsp70 ATPase activity regulates tau stability. J. Neurosci. 2009, 29, 12079-12088
239. Britten, C.D.; Rowinsky, E.K.; Baker, S.D.; Weiss, G.R.; Smith, L.; Stephenson, J.; Rothenberg, M.; Smetzer, L.; Cramer, J.; Collins, W.; et al. A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin. Cancer Res 2000, 6, 42-49
240. Seigneuric, R.; Gobbo, J.; Colas, P.; Garrido, C. Targeting cancer with peptide aptamers. Oncotarget 2011, 2, 557-561
241. Rerole, A.L.; Gobbo, J.; De Thonel, A.; Schmitt, E.; Pais de Barros, J.P.; Hammann, A.; Lanneau, D.; Fourmaux, E.; Demidov, O.N.; Micheau, O.; et al. Peptides and aptamers targeting HSP70: A novel approach for anticancer chemotherapy. Cancer Res. 2011, 71, 484-495
242. Stangl, S.; Gehrmann, M.; Riegger, J.; Kuhs, K.; Riederer, I.; Sievert, W.; Hube, K.; Mocikat, R.; Dressel, R.; Kremmer, E.; et al. Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc. Natl. Acad. Sci. USA 2011, 108, 733-738
243. Krause, S.W.; Gastpar, R.; Andreesen, R.; Gross, C.; Ullrich, H.; Thonigs, G.; Pfister, K.; Multhoff, G. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: A clinical phase I trial. Clin. Cancer Res. 2004, 10, 3699-3707
244. Trimble, C.L.; Peng, S.; Kos, F.; Gravitt, P.; Viscidi, R.; Sugar, E.; Pardoll, D.; Wu, T.C. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin. Cancer Res. 2009, 15, 361-367
245. Kumar, S.; Tomar, M.S.; Acharya, A. HSF1-mediated regulation of tumor cell apoptosis: A novel target for cancer therapeutics. Future Oncol. 2013, 9, 1573-1586
246. Westerheide, S.D.; Kawahara, T.L.; Orton, K.; Morimoto, R.I. Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J. Biol. Chem. 2006, 281, 9616-9622
247. Ermakova, S.P.; Kang, B.S.; Choi, B.Y.; Choi, H.S.; Schuster, T.F.; Ma, W.Y.; Bode, A.M.; Dong, Z. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res. 2006, 66, 9260-9269
248. Chang, L.; Miyata, Y.; Ung, P.M.; Bertelsen, E.B.; McQuade, T.J.; Carlson, H.A.; Zuiderweg, E.R.; Gestwicki, J.E. Chemical screens against a reconstituted multiprotein complex: Myricetin blocks DnaJ regulation of DnaK through an allosteric mechanism. Chem. Biol. 2011, 18, 210-221
249. Williams, D.R.; Ko, S.K.; Park, S.; Lee, M.R.; Shin, I. An apoptosis-inducing small molecule that binds to heat shock protein 70. Angew. Chem. 2008, 47, 7466-7469
250. Balaburski, G.M.; Leu, J.I.; Beeharry, N.; Hayik, S.; Andrake, M.D.; Zhang, G.; Herlyn, M.; Villanueva, J.; Dunbrack, R.L., Jr.; Yen, T.; et al. A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol. Cancer Res. 2013, 11, 219-229
251. Ochiana, S.O.; Taldone, T.; Chiosis, G. Designing Drugs against Hsp90 for Cancer Therapy. In The Molecular Chaperones Interaction Networks in Protein Folding and Degradation; Interactomics and Systems Biology; Houry, W.A., Ed.; Springer: New York, NY, USA, 2014; Volume 1, pp. 151-183.
252. Patel, H.J.; Modi, S.; Chiosis, G.; Taldone, T. Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin. Drug Dis. 2011, 6, 559-587
253. Supko, J.G.; Hickman, R.L.; Grever, M.R.; Malspeis, L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 1995, 36, 305-315
254. Austin, C.D.; De Maziere, A.M.; Pisacane, P.I.; van Dijk, S.M.; Eigenbrot, C.; Sliwkowski, M.X.; Klumperman, J.; Scheller, R.H. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 2004, 15, 5268-5282
255. Castagnola, P.; Bellese, G.; Birocchi, F.; Gagliani, M.C.; Tacchetti, C.; Cortese, K. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells. Oncotarget 2016, 7, 85411-85429
256. Soga, S.; Shiotsu, Y.; Akinaga, S.; Sharma, S.V. Development of radicicol analogues. Curr. Cancer Drug Targets 2003, 3, 359-369
257. Banerji, U.; O’Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino 17-demethoxygeldanamycin in patients with advanced malignancies. J. Clin. Oncol. 2005, 23, 4152-4161
258. Kummar, S.; Gutierrez, M.E.; Gardner, E.R.; Chen, X.; Figg, W.D.; Zajac-Kaye, M.; Chen, M.; Steinberg, S.M.; Muir, C.A.; Yancey, M.A.; et al. Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-D.M.A.G.), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur. J. Cancer 2010, 46, 340-347
259. Lancet, J.E.; Gojo, I.; Burton, M.; Quinn, M.; Tighe, S.M.; Kersey, K.; Zhong, Z.; Albitar, M.X.; Bhalla, K.; Hannah, A.L.; et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010, 24, 699-705
260. Hanson, B.E.; Vesole, D.H. Retaspimycin hydrochloride (IPI-504): A novel heat shock protein inhibitor as an anticancer agent. Expert Opin. Investig. Drugs 2009, 18, 1375-1383
261. Song, D.; Chaerkady, R.; Tan, A.C.; Garcia-Garcia, E.; Nalli, A.; Suarez-Gauthier, A.; Lopez-Rios, F.; Zhang, X.F.; Solomon, A.; Tong, J.; et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor IPI-504 in pancreatic cancer. Mol. Cancer Ther. 2008, 7, 3275-3284
262. Jang, W.J.; Jung, S.K.; Kang, J.S.; Jeong, J.W.; Bae, M.K.; Joo, S.H.; Park, G.H.; Kundu, J.K.; Hong, Y.S.; Jeong, C.H. Anti-tumor activity of WK88-1 a novel geldanamycin derivative in gefitinib-resistant non-small cell lung cancers with Met amplification. Cancer Sci. 2014, 105, 1245-1253
263. Brough, P.A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J.E.; Cheung, K.M.; Collins, I.; Davies, N.G.; Drysdale, M.J.; et al. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: Potential therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51, 196-218
264. Shiotsu, Y.; Neckers, L.M.; Wortman, I.; An, W.G.; Schulte, T.W.; Soga, S.; Murakata, C.; Tamaoki, T.; Akinaga, S. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex. Blood 2000, 96, 2284-2291
265. Ueno, T.; Tsukuda, K.; Toyooka, S.; Ando, M.; Takaoka, M.; Soh, J.; Asano, H.; Maki, Y.; Muraoka, T.; Tanaka, N.; et al. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor on non-small cell lung cancer. Lung Cancer 2012, 76, 26-31
266. Graham, B.; Curry, J.; Smyth, T.; Fazal, L.; Feltell, R.; Harada, I.; Coyle, J.; Williams, B.; Reule, M.; Angove, H.; et al. The heat shock protein 90 inhibitor AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer. Cancer Sci. 2012, 103, 522-527
267. Proia, D.A.; Bates, R.C. Ganetespib and HSP90: Translating preclinical hypotheses into clinical promise. Cancer Res. 2014, 74, 1294-1300
268. Shimamura, T.; Perera, S.A.; Foley, K.P.; Sang, J.; Rodig, S.J.; Inoue, T.; Chen, L.; Li, D.; Carretero, J.; Li, Y.C.; et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clini. Cancer Res. 2012, 18, 4973-4985
269. Acquaviva, J.; Smith, D.L.; Sang, J.; Friedland, J.C.; He, S.; Sequeira, M.; Zhang, C.; Wada, Y.; Proia, D.A. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol. Cancer Ther. 2012, 11, 2633-2643
270. Gomez-Casal, R.; Bhattacharya, C.; Epperly, M.W.; Basse, P.H.; Wang, H.; Wang, X.; Proia, D.A.; Greenberger, J.S.; Socinski, M.A.; Levina, V. The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells. Cancers 2015, 7, 876-907
271. Proia, D.A.; Sang, J.; He, S.; Smith, D.L.; Sequeira, M.; Zhang, C.; Liu, Y.; Ye, S.; Zhou, D.; Blackman, R.K.; et al. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Investig. New Drugs 2012, 30, 2201-2209
272. Socinski, M.A.; Goldman, J.; El-Hariry, I.; Koczywas, M.; Vukovic, V.; Horn, L.; Paschold, E.; Salgia, R.; West, H.; Sequist, L.V.; et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin. Cancer Res. 2013, 19, 3068-3077
273. Ramalingam, S.S.; Zaric, B.; Ceric, T.; Ciuleanu, T.E.; Spicer, J.F.; Bondarenko, I.; Komov, D.; Felip, E.; Carcereny, E.; Von Pawel, J.; et al. Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma. J. Clin. Oncol. 2014, 32, TPS8118.
274. Chatterjee, S.; Huang, E.H.; Christie, I.; Burns, T.F. Reactivation of the p90RSK-CDC25C pathway leads to bypass of the ganetespib induced G2/M arrest and mediates acquired resistance to ganetespib in KRAS mutant NSCLC. Mol. Cancer Ther. 2017
275. Chatterjee, S.; Huang, E.H.; Christie, I.; Kurland, B.F.; Burns, T.F. Acquired Resistance to the Hsp90 Inhibitor Ganetespib in KRAS-Mutant NSCLC is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network. Mol. Cancer Ther. 2017, 16, 793-804
276. Von Hoff, D.; Beeram, M.; O’Brien, S.; Lammanna, N.; Castro, J.; Borad, M.; Burrows, F.; Trone, D.; Woodworth, J.; Tangri, S.; et al. Phase 1 experience with BIIB021 an oral synthetic non-ansamycin Hsp90 inhibitor. Mol. Cancer Ther. 2007, 6, A123.
277. Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim. Biophys. Acta 2012, 1823, 742-755
278. Fadden, P.; Huang, K.H.; Veal, J.M.; Steed, P.M.; Barabasz, A.F.; Foley, B.; Hu, M.; Partridge, J.M.; Rice, J.; Scott, A.; et al. Application of chemoproteomics to drug discovery: Identification of a clinical candidate targeting hsp90. Chem Biol. 2010, 17, 686-694
279. Ohkubo, S.; Kodama, Y.; Muraoka, H.; Hitotsumachi, H.; Yoshimura, C.; Kitade, M.; Hashimoto, A.; Ito, K.; Gomori, A.; Takahashi, K.; et al. TAS-116, a highly selective inhibitor of heat shock protein 90alpha and beta demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models. Mol. Cancer Ther. 2015, 14, 14-22
280. Suzuki, R.; Hideshima, T.; Mimura, N.; Minami, J.; Ohguchi, H.; Kikuchi, S.; Yoshida, Y.; Gorgun, G.; Cirstea, D.; Cottini, F.; et al. Anti-tumor activities of selective HSP90alpha/beta inhibitor TAS-116 in combination with bortezomib in multiple myeloma. Leukemia 2015, 29, 510-514
281. Lee, Y.; Sunada, S.; Hirakawa, H.; Fujimori, A.; Nickoloff, J.A.; Okayasu, R. TAS-116 a Novel Hsp90 Inhibitor Selectively Enhances Radiosensitivity of Human Cancer Cells to X-rays and Carbon Ion Radiation. Mol. Cancer Ther. 2017, 16, 16-24
282. Dorard, C.; de Thonel, A.; Collura, A.; Marisa, L.; Svrcek, M.; Lagrange, A.; Jego, G.; Wanherdrick, K.; Joly, A.L.; Buhard, O.; et al. Expression of a mutant, HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat. Med. 2011, 17, 1283-1289
283. Muchemwa, F.C.; Nakatsura, T.; Fukushima, S.; Nishimura, Y.; Kageshita, T.; Ihn, H. Differential expression of heat shock protein 105 in melanoma and melanocytic naevi. Melanoma Res. 2008, 18, 166-171
284. Zappasodi, R.; Bongarzone, I.; Ghedini, G.C.; Castagnoli, L.; Cabras, A.D.; Messina, A.; Tortoreto, M.; Tripodo, C.; Magni, M.; Carlo-Stella, C.; et al. Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood 2011, 118, 4421-4430
285. Ren, F.; Xu, Y.; Mao, L.; Ou, R.; Ding, Z.; Zhang, X.; Tang, J.; Li, B.; Jia, Z.; Tian, Z.; et al. Heat shock protein 110 improves the antitumor effects of the cytotoxic T lymphocyte epitope E7(49-57) in mice. Cancer Biol. Ther. 2010, 9, 134-141
286. Kim, H.L.; Sun, X.; Subjeck, J.R.; Wang, X.Y. Evaluation of renal cell carcinoma vaccines targeting carbonic anhydrase I.X. using heat shock protein 110. Cancer Immunol. Immunother. 2007, 56, 1097-1105
287. Yokomine, K.; Nakatsura, T.; Senju, S.; Nakagata, N.; Minohara, M.; Kira, J.; Motomura, Y.; Kubo, T.; Sasaki, Y.; Nishimura, Y. Regression of intestinal adenomas by vaccination with heat shock protein 105-pulsed bone marrow-derived dendritic cells in, Apc(Min/+) mice. Cancer Sci. 2007, 98, 1930-1935
288. Manjili, M.H.; Wang, X.Y.; Chen, X.; Martin, T.; Repasky, E.A.; Henderson, R.; Subjeck, J.R. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in, H.E.R-2/neu transgenic mice. J. Immunol. 2003, 171, 4054-4061
289. Wang, X.Y.; Sun, X.; Chen, X.; Facciponte, J.; Repasky, E.A.; Kane, J.; Subjeck, J.R. Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen. J. Immunol. 2010, 184, 6309-6319
290. Ohnishi, K.; Takahashi, A.; Yokota, S.; Ohnishi, T. Effects of a heat shock protein inhibitor KNK437 on heat sensitivity and heat tolerance in human squamous cell carcinoma cell lines differing in p53 status. Int. J. Radiat. Biol. 2004, 80, 607-614
291. Yoon, Y.J.; Kim, J.A.; Shin, K.D.; Shin, D.S.; Han, Y.M.; Lee, Y.J.; Lee, J.S.; Kwon, B.M.; Han, D.C. KRIBB11 inhibits HSP70 synthesis through inhibition of heat shock factor 1 function by impairing the recruitment of positive transcription elongation factor b to the hsp70 promoter. J. Biol. Chem. 2011, 286, 1737-1747
292. Santagata, S.; Mendillo, M.L.; Tang, Y.C.; Subramanian, A.; Perley, C.C.; Roche, S.P.; Wong, B.; Narayan, R.; Kwon, H.; Koeva, M.; et al. Tight coordination of protein translation and HSF1 activation supports the anabolic malignant state. Science 2013, 341, 1238303
293. Salamanca, H.H.; Antonyak, M.A.; Cerione, R.A.; Shi, H.; Lis, J.T. Inhibiting heat shock factor 1 in human cancer cells with a potent RNA aptamer. PLoS ONE 2014, 9, e96330
294. Vilaboa, N.; Bore, A.; Martin-Saavedra, F.; Bayford, M.; Winfield, N.; Firth-Clark, S.; Kirton, S.B.; Voellmy, R. New inhibitor targeting human transcription factor HSF1: Effects on the heat shock response and tumor cell survival. Nucleic Acids Res. 2017, 45, 5797-5817
295. Cao, X.; Bloomston, M.; Zhang, T.; Frankel, W.L.; Jia, G.; Wang, B.; Hall, N.C.; Koch, R.M.; Cheng, H.; Knopp, M.V.; et al. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with, HSP90 inhibitor and glycolysis inhibitor. Clin. Cancer Res. 2008, 14, 1831-1839
296. Davenport, E.L.; Zeisig, A.; Aronson, L.I.; Moore, H.E.; Hockley, S.; Gonzalez, D.; Smith, E.M.; Powers, M.V.; Sharp, S.Y.; Workman, P.; et al. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia 2010, 24, 1804-1807
297. Enmon, R.; Yang, W.H.; Ballangrud, A.M.; Solit, D.B.; Heller, G.; Rosen, N.; Scher, H.I.; Sgouros, G. Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Res. 2003, 63, 8393-8399
298. Dong, H.; Zou, M.; Bhatia, A.; Jayaprakash, P.; Hofman, F.; Ying, Q.; Chen, M.; Woodley, D.T.; Li, W. Breast Cancer MDA-MB-231 Cells Use Secreted Heat Shock Protein-90alpha (Hsp90alpha) to Survive a Hostile Hypoxic Environment. Sci. Rep. 2016, 6, 20605
299. Falahi, F.; Sgro, A.; Blancafort, P. Epigenome engineering in cancer: Fairytale or a realistic path to the clinic? Front. Oncol. 2015, 5, 22
300. Murakami, N.; Kuhnel, A.; Schmid, T.E.; Ilicic, K.; Stangl, S.; Braun, I.S.; Gehrmann, M.; Molls, M.; Itami, J.; Multhoff, G. Role of membrane Hsp70 in radiation sensitivity of tumor cells. Radiat. Oncol. 2015, 10, 149
301. Sauvage, F.; Messaoudi, S.; Fattal, E.; Barratt, G.; Vergnaud-Gauduchon, J. Heat shock proteins and cancer: How can nanomedicine be harnessed? J. Controll. Rel. 2017, 248, 133-143
302. Binder, R.J. Functions of heat shock proteins in pathways of the innate and adaptive immune system. J. Immunol. 2014, 193, 5765-5771
303. Segal, B.H.; Wang, X.Y.; Dennis, C.G.; Youn, R.; Repasky, E.A.; Manjili, M.H.; Subjeck, J.R. Heat shock proteins as vaccine adjuvants in infections and cancer. Drug Discov. Today 2006, 11, 534-540
304. Shevtsov, M.; Multhoff, G. Heat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of Cancer. Front. Immunol. 2016, 7, 171